Anorexia nervosa (AN) is a major psychiatric disorder associated with life-threatening medical complications, significant chronicity, and less than optimal outcomes including high mortality rates. Startlingly, there has been limited study of the treatment of AN. Treatment studies to date, including the use of pharmacologic agents such as the serotonin (5-HT) selective reuptake inhibitors (SSRIs), show limited success in AN. Previous studies of CSF metabolites, pharmacological neuroendocrine and behavioral responses, and PET imaging studies have shown that low weight patients with AN have decreased pre- and post-synaptic 5-HT responsiveness. Similar studies have shown increasing 5-HT responsiveness as patients gain weight and achieve symptom remission. Dysregulation of 5-HT function in AN is potentially quite important as it may play a significant role in the disabling behavioral symptoms, as well as in the tendency for relapse and chronicity. Decreased central nervous system 5-HT function may contribute to the refractoriness of the disorder to pharmacological interventions. Given the potential importance of these findings in suggesting ? new treatment approaches for AN, this study examines the possible therapeutic implications of precursor augmentation to enhance 5-HT functioning in patients with AN. This study utilizes a double-blind randomized placebo-controlled design to test the hypothesis that, in subjects with AN, short-term augmentation with a 5- HT precursor enhances 5-HT function in comparison to an SSRI alone as measured by behavioral and neuroendocrine responses. Subjects include 54 women with AN, 36 women who have recovered from AN, and 54 healthy controls. AN and control subjects are randomized to one of three short-term medication conditions: placebo, fluoxetine, or fluoxetine plus 5- hydroxytryptophan (5-HTP). Recovered AN subjects are randomized to short-term placebo or fluoxetine conditions. Results of this project will help to clarify the usefulness of precursor augmentation as a possible new treatment approach for this devastating disorder. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH057395-04A1
Application #
6824394
Study Section
Interventions Research Review Committee (ITV)
Program Officer
Chavez, Mark
Project Start
1998-08-01
Project End
2009-08-31
Budget Start
2004-09-09
Budget End
2005-08-31
Support Year
4
Fiscal Year
2004
Total Cost
$243,338
Indirect Cost
Name
Boston College
Department
Psychiatry
Type
Schools of Nursing
DUNS #
045896339
City
Chestnut Hill
State
MA
Country
United States
Zip Code
02467
Wolfe, Barbara E; Kelly-Weeder, Susan; Malcom, Alexis W et al. (2013) Accuracy of self-reported body weight and height in remitted anorexia nervosa. J Am Psychiatr Nurses Assoc 19:66-70
Wolfe, Barbara E; Jimerson, David C; Smith, Adrian et al. (2011) Serum amylase in bulimia nervosa and purging disorder: differentiating the association with binge eating versus purging behavior. Physiol Behav 104:684-6
Daley, Karen A; Jimerson, David C; Heatherton, Todd F et al. (2008) State self-esteem ratings in women with bulimia nervosa and bulimia nervosa in remission. Int J Eat Disord 41:159-63
Wolfe, Barbara E; Jimerson, David C; Orlova, Christine et al. (2004) Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) 61:332-8
Wolfe, Barbara E; Gimby, Laura B (2003) Caring for the hospitalized patient with an eating disorder. Nurs Clin North Am 38:75-99
Wolfe, B E; Metzger, E D; Levine, J M et al. (2001) Laboratory screening for electrolyte abnormalities and anemia in bulimia nervosa: a controlled study. Int J Eat Disord 30:288-93